Imatinib Grindeks (Imatinib)

Imatinib selectively binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT, and PDGFR tyrosine kinases, locking them in an inactive state. This blocks downstream signaling pathways that drive uncontrolled cell growth, leading to apoptosis of the malignant cells that rely on these kinases.

The dose of Imatinib Grindeks is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and concomitant medications. Patients should follow the exact regimen written on their prescription.

Imatinib is classified as a potential risk to the fetus and is generally not recommended during pregnancy unless the benefits outweigh the risks. Breastfeeding is also discouraged because the drug can be excreted in milk. Women of child‑bearing potential should discuss contraception and pregnancy planning with their healthcare provider.

To request Imatinib Grindeks, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor and is well‑established for CML and GIST. Newer agents such as dasatinib or nilotinib have higher potency and may be preferred in cases of resistance or intolerance to imatinib, but they also carry distinct safety profiles. Choice of therapy depends on disease characteristics, prior treatment history, and patient tolerance.

Imatinib Grindeks should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture, light, and humidity. Do not store in the bathroom or near heat sources, and keep the product out of reach of children.

Imatinib Grindeks is taken orally, usually once daily, with or without food according to the prescriber’s instructions. The tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically advised by a healthcare professional.

The most serious adverse events include severe neutropenia or thrombocytopenia, hepatotoxicity with marked liver enzyme elevations, cardiac failure or reduced left‑ventricular ejection fraction, pulmonary arterial hypertension, and life‑threatening hemorrhage. Patients should be monitored regularly for these complications.

Patients with known hypersensitivity to imatinib or any of its excipients should not use the product. Caution is also advised for individuals with severe hepatic impairment, uncontrolled cardiac disease, or those who are pregnant or breastfeeding without a clear risk‑benefit assessment by their physician.